Treatment with a dual COX/5-LOX inhibitor, tepoxalin, led to oxidative damage, induced apoptosis and exhibited a synergistic effect with doxorubicin in reducing cell proliferation in canine osteosarcoma cell lines [129]. This evidence concerns the gene ALOX5 and osteosarcoma.